ATH 0.00% 0.3¢ alterity therapeutics limited

Using similar science, page-24

  1. 5,922 Posts.
    lightbulb Created with Sketch. 151
    OK Copper, so I should not mention the microbleeds and brain swelling which were experienced in an early MAB amyloid targeting trial, which are still possibly a problem with other MABs, but then you go ahead and bring up a drug Prana dropped over a decade ago. Are you serious.
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.